{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T01:10:45Z","timestamp":1791508245607,"version":"4.3.4"},"reference-count":32,"publisher":"American Society of Hematology","issue":"8","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,4,27]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>CD19-directed chimeric antigen receptor (CAR) T-cell therapy has shown efficacy as a third-line or later treatment in patients with relapsed\/refractory large B-cell lymphoma (LBCL). Using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) and the EuroQol 5-Dimension 5-Level (EQ-5D-5L) questionnaire, we evaluated the impact of CAR T-cell treatment with lisocabtagene maraleucel (liso-cel) on health-related quality of life (HRQoL) and symptoms in patients with relapsed\/refractory LBCL in the ongoing, open-label, nonrandomized TRANSCEND NHL 001 trial. Clinically meaningful improvement was observed in EORTC QLQ-C30 scores for global health status\/QoL, based on a minimally important difference of 10 points at 2 to 18 months after liso-cel infusion. There were no clinically meaningful changes in physical functioning and pain, whereas clinically meaningful improvements were observed in fatigue at 2, 12, and 18 months. The proportion of patients with clinically meaningful improvement in global health status\/QoL was generally higher for treatment responders than for nonresponders. A trend toward decreased mean EQ-5D-5L index scores was observed at 1 month after liso-cel infusion, followed by subsequent increases through 18 months. Mean EQ-5D-5L visual analog scale scores increased from 2 through 18 months. In summary, patients with relapsed\/refractory LBCL treated with liso-cel had early, sustained, and clinically meaningful improvements in HRQoL and symptoms that correlated with antitumor activity. This study was registered at www.clinicaltrials.gov as #NCT02631044.<\/jats:p>","DOI":"10.1182\/bloodadvances.2020003503","type":"journal-article","created":{"date-parts":[[2021,4,28]],"date-time":"2021-04-28T09:54:18Z","timestamp":1619603658000},"page":"2245-2255","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":34,"title":["Effect of lisocabtagene maraleucel on HRQoL and symptom severity in relapsed\/refractory large B-cell lymphoma"],"prefix":"10.1182","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0756-0492","authenticated-orcid":false,"given":"Donald L.","family":"Patrick","sequence":"first","affiliation":[{"name":"Department of Health Services, University of Washington, Seattle, WA;"},{"name":"Fred Hutchinson Cancer Research Center, Seattle, WA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annette","family":"Powers","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb, Princeton, NJ; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika Parisi","family":"Jun","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb, Princeton, NJ; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeonhee","family":"Kim","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob","family":"Garcia","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Dehner","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David G.","family":"Maloney","sequence":"additional","affiliation":[{"name":"Fred Hutchinson Cancer Research Center, Seattle, WA;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2021,4,27]]},"reference":[{"issue":"20","key":"2021042715325068100_B1","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"key":"2021042715325068100_B2","volume-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"IARC","year":"2017","edition":"4th ed, revised"},{"issue":"1","key":"2021042715325068100_B3","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1182\/blood-2005-06-2508","article-title":"Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001","volume":"107","author":"Morton","year":"2006","journal-title":"Blood"},{"issue":"6","key":"2021042715325068100_B4","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1200\/JCO.2014.56.2025","article-title":"Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor","volume":"33","author":"Kochenderfer","year":"2015","journal-title":"J Clin Oncol"},{"issue":"52","key":"2021042715325068100_B5","doi-asserted-by":"crossref","first-page":"29843","DOI":"10.18632\/oncotarget.25688","article-title":"CD19 directed CAR T cell therapy in diffuse large B-cell lymphoma","volume":"9","author":"Quint\u00e1s-Cardama","year":"2018","journal-title":"Oncotarget"},{"issue":"10254","key":"2021042715325068100_B6","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"issue":"3","key":"2021042715325068100_B7","doi-asserted-by":"crossref","first-page":"400","DOI":"10.3109\/10428194.2010.541310","article-title":"Quality of life in patients with diffuse large B-cell lymphoma treated with dose-dense chemotherapy is only affected temporarily","volume":"52","author":"Tholstrup","year":"2011","journal-title":"Leuk Lymphoma"},{"issue":"10","key":"2021042715325068100_B8","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1007\/s00277-014-2099-8","article-title":"Health-related quality of life and persistent symptoms in relation to (R-)CHOP14, (R-)CHOP21, and other therapies among patients with diffuse large B-cell lymphoma: results of the population-based PHAROS-registry","volume":"93","author":"Oerlemans","year":"2014","journal-title":"Ann Hematol"},{"issue":"5","key":"2021042715325068100_B9","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1007\/s00277-013-1980-1","article-title":"Quality of life more impaired in younger than in older diffuse large B cell lymphoma survivors compared to a normative population: a study from the population-based PROFILES registry","volume":"93","author":"van der Poel","year":"2014","journal-title":"Ann Hematol"},{"issue":"16","key":"2021042715325068100_B10","doi-asserted-by":"crossref","first-page":"2857","DOI":"10.1002\/cncr.29427","article-title":"Age-related differences in quality of life among patients with diffuse large B-cell lymphoma","volume":"121","author":"Oerlemans","year":"2015","journal-title":"Cancer"},{"issue":"16","key":"2021042715325068100_B11","doi-asserted-by":"crossref","first-page":"2858","DOI":"10.1002\/cncr.29425","article-title":"Reply to age-related differences in quality of life among patients with diffuse large B-cell lymphoma","volume":"121","author":"Williams","year":"2015","journal-title":"Cancer"},{"issue":"2","key":"2021042715325068100_B12","doi-asserted-by":"crossref","first-page":"79","DOI":"10.3960\/jslrt.56.79","article-title":"Treatment of diffuse large B-cell lymphoma","volume":"56","author":"Miyazaki","year":"2016","journal-title":"J Clin Exp Hematop"},{"key":"2021042715325068100_B13","volume-title":"KYMRIAH\u00ae (tisagenlecleucel). Prescribing information","year":"2018"},{"key":"2021042715325068100_B14","volume-title":"YESCARTA\u00ae (axicabtagene ciloleucel). Prescribing information","year":"2020"},{"issue":"5","key":"2021042715325068100_B15","doi-asserted-by":"crossref","first-page":"e155","DOI":"10.1016\/j.bbmt.2018.11.025","article-title":"Patient-reported outcomes with chimeric antigen receptor T cell therapy: challenges and opportunities","volume":"25","author":"Chakraborty","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"7","key":"2021042715325068100_B16","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.3109\/10428194.2011.566951","article-title":"Quality of life in 269 patients with poor-risk diffuse large B-cell lymphoma treated with rituximab versus observation after autologous stem cell transplant","volume":"52","author":"Heutte","year":"2011","journal-title":"Leuk Lymphoma"},{"key":"2021042715325068100_B17","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2019-127145","article-title":"Impact of liso-cel treatment on health-related quality of life and health utility in patients with relapsed\/refractory aggressive B-cell non-Hodgkin lymphoma: TRANSCEND NHL 001.","volume-title":"61st American Society of Hematology Annual Meeting and Exposition","author":"Patrick","year":"2019"},{"key":"2021042715325068100_B18","author":"European Organisation for Research and Treatment of Cancer","year":"2001"},{"issue":"1","key":"2021042715325068100_B19","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1200\/JCO.1998.16.1.139","article-title":"Interpreting the significance of changes in health-related quality-of-life scores","volume":"16","author":"Osoba","year":"1998","journal-title":"J Clin Oncol"},{"key":"2021042715325068100_B20","author":"van Reenen","year":"2015"},{"issue":"1","key":"2021042715325068100_B21","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/1477-7525-5-70","article-title":"Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer","volume":"5","author":"Pickard","year":"2007","journal-title":"Health Qual Life Outcomes"},{"issue":"1","key":"2021042715325068100_B22","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.bbmt.2019.09.037","article-title":"Patient-reported neuropsychiatric outcomes of long-term survivors after chimeric antigen receptor T cell therapy","volume":"26","author":"Ruark","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"2021042715325068100_B23","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"key":"2021042715325068100_B24","author":"Maziarz","year":"2017"},{"issue":"4","key":"2021042715325068100_B25","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1182\/bloodadvances.2019001026","article-title":"Patient-reported long-term quality of life after tisagenlecleucel in relapsed\/refractory diffuse large B-cell lymphoma","volume":"4","author":"Maziarz","year":"2020","journal-title":"Blood Adv"},{"key":"2021042715325068100_B26","author":"Sidana","year":"2019"},{"issue":"10","key":"2021042715325068100_B27","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1093\/annonc\/mdq721","article-title":"Choosing between the EORTC QLQ-C30 and FACT-G for measuring health-related quality of life in cancer clinical research: issues, evidence and recommendations","volume":"22","author":"Luckett","year":"2011","journal-title":"Ann Oncol"},{"issue":"11","key":"2021042715325068100_B28","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1080\/10428194.2019.1602262","article-title":"Patient-reported outcomes in KEYNOTE-087, a phase 2 study of pembrolizumab in patients with classical Hodgkin lymphoma","volume":"60","author":"von Tresckow","year":"2019","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"2021042715325068100_B29","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.3324\/haematol.2019.222299","article-title":"Health-related quality of life in transplant ineligible newly diagnosed multiple myeloma patients treated with either thalidomide or lenalidomide-based regimen until progression: a prospective, open-label, multicenter, randomized, phase 3 study","volume":"105","author":"Nielsen","year":"2020","journal-title":"Haematologica"},{"issue":"1","key":"2021042715325068100_B30","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1200\/JCO.2010.28.0107","article-title":"Evidence-based guidelines for determination of sample size and interpretation of the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30","volume":"29","author":"Cocks","year":"2011","journal-title":"J Clin Oncol"},{"issue":"11","key":"2021042715325068100_B31","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1016\/j.ejca.2012.02.059","article-title":"Evidence-based guidelines for interpreting change scores for the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30","volume":"48","author":"Cocks","year":"2012","journal-title":"Eur J Cancer"},{"issue":"2","key":"2021042715325068100_B32","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1586\/erp.11.9","article-title":"A point of minimal important difference (MID): a critique of terminology and methods","volume":"11","author":"King","year":"2011","journal-title":"Expert Rev Pharmacoecon Outcomes Res"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/5\/8\/2245\/1806071\/advancesadv2020003503.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/5\/8\/2245\/1806071\/advancesadv2020003503.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,28]],"date-time":"2021-04-28T09:54:40Z","timestamp":1619603680000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/5\/8\/2245\/475826\/Effect-of-lisocabtagene-maraleucel-on-HRQoL-and"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,27]]},"references-count":32,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021,4,27]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2020003503","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,27]]}}}